查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1982812

全球視神經疾病治療市場：規模、佔有率、趨勢和成長分析報告（2026-2034）

Global Optic Nerve Disorders Treatment Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 229 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計視神經疾病治療市場規模將從 2025 年的 27.9 億美元成長到 2034 年的 43.9 億美元，2026 年至 2034 年的複合年成長率為 5.17%。

隨著視力相關健康問題的日益普遍，全球視神經疾病治療市場的重要性也日益凸顯。視神經疾病可導致視力障礙甚至失明，其病因包括青光眼、發炎或神經損傷等。有效的治療對於保護視力、防止進一步損害至關重要。

多種因素正在推動視神經疾病治療市場的成長。人口老化和眼科疾病率的上升催生了對專業眼科治療的需求。此外，診斷影像技術的進步也提高了視神經疾病的早期發現和治療方案製定。

隨著眼科醫學研究的不斷深入，視神經疾病治療市場預計將會擴大。創新治療方法和診斷技術的進步可望提升治療效果。此外，人們對眼部健康的日益重視以及專業眼科醫療服務的普及也將促進市場成長。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章：全球視神經疾病治療市場：依適應症分類

  • 市場分析、洞察與預測
  • 青光眼
  • 視神經炎
  • 視神經膠質瘤
  • 視神經乳頭狀疣
  • 視神經缺損
  • 視神經萎縮
  • 其他

第5章 全球視神經疾病治療市場：依藥物類別分類

  • 市場分析、洞察與預測
  • BETA阻斷劑
  • 前列腺素
  • α腎上腺素促效劑
  • 碳酸酐酶抑制劑
  • 抗生素
  • 皮質類固醇
  • 其他

第6章 全球視神經疾病治療市場：依診斷分類

  • 市場分析、洞察與預測
  • 影像檢查
  • 眼底鏡檢查
  • 眼科檢查

第7章 全球視神經疾病治療市場：依劑型分類

  • 市場分析、洞察與預測
  • 藥片
  • 注射藥物
  • 解決方案
  • 其他

第8章 全球視神經疾病治療市場：依最終用戶分類

  • 市場分析、洞察與預測
  • 醫院
  • 專科診所
  • 居家照護
  • 其他

第9章 全球視神經疾病治療市場：依通路分類

  • 市場分析、洞察與預測
  • 醫院藥房
  • 零售藥房
  • 網路藥房

第10章 全球視神經疾病治療市場：依地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第11章 競爭格局

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第12章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • F. Hoffmann-La Roche Ltd
    • Mylan NV
    • Teva Pharmaceutical Industries Ltd
    • Sanofi
    • Pfizer Inc
    • GlaxoSmithKline Plc
    • Novartis AG
    • Zydus Cadila
    • Boehringer Ingelheim International GmbH
    • Apotex Inc
    • AstraZeneca
    • Johnson & Johnson
    • Bayer AG
    • Sun Pharmaceutical Industries Ltd
    • LEO Pharma A/S
簡介目錄
Product Code: VMR11212603

The Optic Nerve Disorders Treatment Market size is expected to reach USD 4.39 Billion in 2034 from USD 2.79 Billion (2025) growing at a CAGR of 5.17% during 2026-2034.

The global optic nerve disorders treatment market has gained importance as vision-related health issues become more prevalent. Optic nerve disorders can lead to vision impairment or blindness and may result from conditions such as glaucoma, inflammation, or nerve damage. Effective treatment is essential to protect vision and prevent further damage.

Several factors are driving the growth of the optic nerve disorders treatment market. Increasing aging populations and rising prevalence of eye diseases have created demand for specialized ophthalmic treatments. Additionally, advancements in diagnostic imaging technologies have improved early detection and treatment planning for optic nerve conditions.

In the future, the optic nerve disorders treatment market is expected to grow as research in ophthalmology continues to advance. Development of innovative therapies and improved diagnostic techniques may enhance treatment outcomes. Furthermore, increasing awareness about eye health and access to specialized eye care services will likely support market growth.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Indication

  • Glaucoma
  • Optic Neuritis
  • Optic Nerve Gliomas
  • Optic Nerve Drusen
  • Optic Nerve Coloboma
  • Optic Atrophy
  • Others

By Drug Class

  • Beta Blockers
  • Prostaglandins
  • Alpha Adrenergic Agonist
  • Carbonic Anhydrase Inhibitors
  • Antibiotics
  • Corticosteroids
  • Others

By Diagnosis

  • Imaging Tests
  • Ophthalmoscopy
  • Eye exams

By Dosage form

  • Tablets
  • Injections
  • Solution
  • Others

By End-Users

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

COMPANIES PROFILED

  • F HoffmannLa Roche Ltd, Mylan NV, Teva Pharmaceutical Industries Ltd, Sanofi, Pfizer Inc, GlaxoSmithKline plc, Novartis AG, Zydus Cadila, Boehringer Ingelheim International GmbH, Apotex Inc, AstraZeneca, Johnson Johnson, Bayer AG, Sun Pharmaceutical Industries Ltd, LEO Pharma AS
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL OPTIC NERVE DISORDERS TREATMENT MARKET: BY INDICATION 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Indication
  • 4.2. Glaucoma Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Optic Neuritis Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Optic Nerve Gliomas Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. Optic Nerve Drusen Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.6. Optic Nerve Coloboma Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.7. Optic Atrophy Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.8. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL OPTIC NERVE DISORDERS TREATMENT MARKET: BY DRUG CLASS 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Drug Class
  • 5.2. Beta Blockers Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Prostaglandins Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Alpha Adrenergic Agonist Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.5. Carbonic Anhydrase Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.6. Antibiotics Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.7. Corticosteroids Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.8. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL OPTIC NERVE DISORDERS TREATMENT MARKET: BY DIAGNOSIS 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Diagnosis
  • 6.2. Imaging Tests Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Ophthalmoscopy Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Eye exams Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL OPTIC NERVE DISORDERS TREATMENT MARKET: BY DOSAGE FORM 2022-2034 (USD MN)

  • 7.1. Market Analysis, Insights and Forecast Dosage Form
  • 7.2. Tablets Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.3. Injections Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.4. Solution Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL OPTIC NERVE DISORDERS TREATMENT MARKET: BY END-USERS 2022-2034 (USD MN)

  • 8.1. Market Analysis, Insights and Forecast End-users
  • 8.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 8.3. Specialty Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 8.4. Homecare Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 8.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL OPTIC NERVE DISORDERS TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

  • 9.1. Market Analysis, Insights and Forecast Distribution Channel
  • 9.2. Hospital Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 9.3. Retail Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 9.4. Online Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 10. GLOBAL OPTIC NERVE DISORDERS TREATMENT MARKET: BY REGION 2022-2034(USD MN)

  • 10.1. Regional Outlook
  • 10.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 10.2.1 By Indication
    • 10.2.2 By Drug Class
    • 10.2.3 By Diagnosis
    • 10.2.4 By Dosage Form
    • 10.2.5 By End-users
    • 10.2.6 By Distribution Channel
    • 10.2.7 United States
    • 10.2.8 Canada
    • 10.2.9 Mexico
  • 10.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 10.3.1 By Indication
    • 10.3.2 By Drug Class
    • 10.3.3 By Diagnosis
    • 10.3.4 By Dosage Form
    • 10.3.5 By End-users
    • 10.3.6 By Distribution Channel
    • 10.3.7 United Kingdom
    • 10.3.8 France
    • 10.3.9 Germany
    • 10.3.10 Italy
    • 10.3.11 Russia
    • 10.3.12 Rest Of Europe
  • 10.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 10.4.1 By Indication
    • 10.4.2 By Drug Class
    • 10.4.3 By Diagnosis
    • 10.4.4 By Dosage Form
    • 10.4.5 By End-users
    • 10.4.6 By Distribution Channel
    • 10.4.7 India
    • 10.4.8 Japan
    • 10.4.9 South Korea
    • 10.4.10 Australia
    • 10.4.11 South East Asia
    • 10.4.12 Rest Of Asia Pacific
  • 10.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 10.5.1 By Indication
    • 10.5.2 By Drug Class
    • 10.5.3 By Diagnosis
    • 10.5.4 By Dosage Form
    • 10.5.5 By End-users
    • 10.5.6 By Distribution Channel
    • 10.5.7 Brazil
    • 10.5.8 Argentina
    • 10.5.9 Peru
    • 10.5.10 Chile
    • 10.5.11 South East Asia
    • 10.5.12 Rest of Latin America
  • 10.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 10.6.1 By Indication
    • 10.6.2 By Drug Class
    • 10.6.3 By Diagnosis
    • 10.6.4 By Dosage Form
    • 10.6.5 By End-users
    • 10.6.6 By Distribution Channel
    • 10.6.7 Saudi Arabia
    • 10.6.8 UAE
    • 10.6.9 Israel
    • 10.6.10 South Africa
    • 10.6.11 Rest of the Middle East And Africa

Chapter 11. COMPETITIVE LANDSCAPE

  • 11.1. Recent Developments
  • 11.2. Company Categorization
  • 11.3. Supply Chain & Channel Partners (based on availability)
  • 11.4. Market Share & Positioning Analysis (based on availability)
  • 11.5. Vendor Landscape (based on availability)
  • 11.6. Strategy Mapping

Chapter 12. COMPANY PROFILES OF GLOBAL OPTIC NERVE DISORDERS TREATMENT INDUSTRY

  • 12.1. Top Companies Market Share Analysis
  • 12.2. Company Profiles
    • 12.2.1 F. Hoffmann-La Roche Ltd
    • 12.2.2 Mylan N.V
    • 12.2.3 Teva Pharmaceutical Industries Ltd
    • 12.2.4 Sanofi
    • 12.2.5 Pfizer Inc
    • 12.2.6 GlaxoSmithKline Plc
    • 12.2.7 Novartis AG
    • 12.2.8 Zydus Cadila
    • 12.2.9 Boehringer Ingelheim International GmbH
    • 12.2.10 Apotex Inc
    • 12.2.11 AstraZeneca
    • 12.2.12 Johnson & Johnson
    • 12.2.13 Bayer AG
    • 12.2.14 Sun Pharmaceutical Industries Ltd
    • 12.2.15 LEO Pharma A/S